In summary, combined anti-PD-1/G007-LK treatment of B16-F10 tumors is dependent on tankyrase inhibitor-mediated loss of β-catenin in the tumor and induces an IFNγ and CD8+ T cell-dependent growth-inhibitory effect. Here, CD8A is linked to neoplasm.